
Tirzepatide Cuts BMI Sharply in Adolescents With Obesity, Phase III Trial Finds
Tirzepatide (Zepbound) produced substantial reductions in body mass index among adolescents with obesity in the phase III SURMOUNT-ADOLESCENTS trial. At week 72, participants on the once-weekly GLP-1/GIP drug alongside a healthy lifestyle program saw an 18.5% mean BMI reduction, while those on placebo saw a 0.5% increase. The trial met its primary endpoint, and all 10 key secondary outcomes also favored tirzepatide. Results were presented at the ObesityWeek annual meeting and published in JAMA. The researchers cautioned against escalating doses to the maximum tolerated level in routine care.